An analysis by researchers at the University of Oxford has found that the AstraZeneca (AZ)/Oxford coronavirus vaccine appears more effective when its two doses are administered three months apart, results in line with those unveiled by AZ earlier this month. Read More

A study conducted in Israel, which has already vaccinated a large percentage of its population, has found that a single dose of Pfizer/BioNTech’s COVID-19 vaccine is highly effective at reducing infection, lending more support to the strategy of delaying second doses to increase initial vaccinations. Read More

Pfizer and BioNTech announced that they have dosed the first patients in a global study evaluating their COVID-19 vaccine in pregnant women 18 years and over. Read More

A statistical analysis of multiple clinical trials that assessed Fujifilm’s antiviral Avigan (favipiravir) as a COVID-19 treatment has found that the drug showed limited efficacy in reducing mortality unless given early to infected patients. Read More

The U.S. should postpone second doses of the Pfizer/BioNTech COVID-19 vaccine in order to conserve supply and inoculate as many people as possible, two Canadian researchers recommended, citing data showing the initial dose to be highly effective. Read More

A specially convened UK clinical trial ethics committee has given the go-ahead for a COVID-19 human challenge study that is slated to start within weeks to help inform further vaccine and treatment research. Read More

Efforts to reach large-scale production of a COVID-19 vaccine modified to address new viral variants could take AstraZeneca (AZ) at least six months to achieve, according to company documents. Read More

Roche’s anti-inflammatory drug Actemra (tocilizumab) has been shown to reduce COVID-19-related deaths in the UK’s RECOVERY trial of multiple potential treatments. Read More

The University of Oxford has announced that it has begun the first study of the AstraZeneca (AZ)/Oxford coronavirus vaccine in children and young adults to evaluate if the inoculation is safe and effective in patients aged six to 17. Read More